Effect of inosiplex (Isoprinosine®) on induced human influenza A infection

Publisher Website
Google Scholar
Abstract
A double blind prospective controlled study to evaluate the effect of inosiplex in induced human influenza A infection was carried out. Inosiplex was administered in therapeutic (starting 48 h following challenge) or prophylactic-therapeutic (starting 48 h prior to challenge) manner in a dose of 4 g per day. Although the number of volunteers with clinical illness in the two treatment groups was not significantly different as compared to placebo, the volunteers had significantly fewer and less severe symptoms. Average symptom scores for headache, myalgia and malaise were significantly reduced in both treatment groups as compared to placebo. Rhinorrhoea was significantly reduced in the prophylactic-therapeutic group but not in the therapeutic group otherwise there were no significant differences between the two treatment groups. Enhancement of lymphocyte transformation in presence of PHA was noted at 2 and 4 days post challenge in treatment groups as compared to placebo. Inosiplex was effective in reducing symptoms of influenza. Its effect may be related at least in part to its immunopotentiating activity.

This publication has 2 references indexed in Scilit: